Arcutis Biotherapeutics reported robust Q3 2025 results, with net product revenues of $99.2 million, reflecting a substantial 122% year-over-year increase driven by strong demand for its ZORYVE portfolio.

• Net product revenues increased 22% sequentially and 122% compared to Q3 2024, fueled by growing prescription volumes across ZORYVE formulations.
• Total prescriptions for ZORYVE rose 13% from Q2 and 92% year-over-year, reaching record weekly averages with over 17,000 scripts.
• The recent launch of ZORYVE cream 0.05% for atopic dermatitis (ages 2-5) is expected to further drive sales in the upcoming quarter.
• R&D expenses remain stable year-over-year at $19.6 million, with anticipated increases in 2026 for further clinical developments.
• Arcutis is nearing cash flow positivity, enabling sustained business investments and growth in the dermatology sector.